检查COVID-19大流行对爱尔兰浸润性乳腺癌发病率的影响：一项基于人群的研究

IF 2.4 3区医学 Q3 ONCOLOGY

Cancer Epidemiology Pub Date : 2025-07-07 DOI:10.1016/j.canep.2025.102864

Jessica O’Driscoll , Paula A. Tierney , Joe McDevitt , Aline Brennan , Maria Theresa Redaniel , Mengyang Zhang , Kathleen Bennett , Deirdre Murray , Maeve Mullooly

{"title":"检查COVID-19大流行对爱尔兰浸润性乳腺癌发病率的影响：一项基于人群的研究","authors":"Jessica O’Driscoll , Paula A. Tierney , Joe McDevitt , Aline Brennan , Maria Theresa Redaniel , Mengyang Zhang , Kathleen Bennett , Deirdre Murray , Maeve Mullooly","doi":"10.1016/j.canep.2025.102864","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>This study aimed to investigate the COVID-19 impact on invasive breast cancer incidence and one-year survival in Ireland.</div></div><div><h3>Methods</h3><div>Anonymised aggregate population data from the National Cancer Registry Ireland were used to examine incidence between 2014 and 2020 and differences in the distribution of clinical characteristics using chi-squared tests. Negative binomial regression examined the association between incidence and year of diagnosis. One-year survival was examined by year of diagnosis using Cox proportional hazards regression modelling.</div></div><div><h3>Results</h3><div>For 2020, the age-standardised incidence rate (ASR, per 100,000 females) was 131.9, compared to 163.9 for 2019. In 2020, the incidence rate significantly declined (IRR = 0.41, 95 % CI = 0.22, 0.75) relative to 2019. Fewer cases presented through organised screening (-62.3 %), while similar or increased numbers presented with symptoms (0.1 %) and via other methods (9.0 %) respectively in 2020, compared to 2019. Significant differences were observed in case distribution by ER status (p = 0.02) and stage (p < 0.01) between 2019 and 2020. One-year survival was similar for cases diagnosed during 2014–2019 and in 2020 (HR = 1.07, 95 % CI = 0.89, 1.27).</div></div><div><h3>Conclusions</h3><div>These findings demonstrate reductions in invasive breast cancer incidence and no difference in one-year survival following the pandemic onset. Additional studies to determine the longer-term COVID-19 impact are needed.</div></div>","PeriodicalId":56322,"journal":{"name":"Cancer Epidemiology","volume":"97 ","pages":"Article 102864"},"PeriodicalIF":2.4000,"publicationDate":"2025-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Examining the impact of the COVID-19 pandemic on invasive breast cancer incidence in Ireland: A population-based study\",\"authors\":\"Jessica O’Driscoll , Paula A. Tierney , Joe McDevitt , Aline Brennan , Maria Theresa Redaniel , Mengyang Zhang , Kathleen Bennett , Deirdre Murray , Maeve Mullooly\",\"doi\":\"10.1016/j.canep.2025.102864\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><div>This study aimed to investigate the COVID-19 impact on invasive breast cancer incidence and one-year survival in Ireland.</div></div><div><h3>Methods</h3><div>Anonymised aggregate population data from the National Cancer Registry Ireland were used to examine incidence between 2014 and 2020 and differences in the distribution of clinical characteristics using chi-squared tests. Negative binomial regression examined the association between incidence and year of diagnosis. One-year survival was examined by year of diagnosis using Cox proportional hazards regression modelling.</div></div><div><h3>Results</h3><div>For 2020, the age-standardised incidence rate (ASR, per 100,000 females) was 131.9, compared to 163.9 for 2019. In 2020, the incidence rate significantly declined (IRR = 0.41, 95 % CI = 0.22, 0.75) relative to 2019. Fewer cases presented through organised screening (-62.3 %), while similar or increased numbers presented with symptoms (0.1 %) and via other methods (9.0 %) respectively in 2020, compared to 2019. Significant differences were observed in case distribution by ER status (p = 0.02) and stage (p < 0.01) between 2019 and 2020. One-year survival was similar for cases diagnosed during 2014–2019 and in 2020 (HR = 1.07, 95 % CI = 0.89, 1.27).</div></div><div><h3>Conclusions</h3><div>These findings demonstrate reductions in invasive breast cancer incidence and no difference in one-year survival following the pandemic onset. Additional studies to determine the longer-term COVID-19 impact are needed.</div></div>\",\"PeriodicalId\":56322,\"journal\":{\"name\":\"Cancer Epidemiology\",\"volume\":\"97 \",\"pages\":\"Article 102864\"},\"PeriodicalIF\":2.4000,\"publicationDate\":\"2025-07-07\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cancer Epidemiology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1877782125001249\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Epidemiology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1877782125001249","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

本研究旨在调查COVID-19对爱尔兰浸润性乳腺癌发病率和一年生存率的影响。方法使用来自爱尔兰国家癌症登记处的匿名汇总人口数据，使用卡方检验检查2014年至2020年之间的发病率和临床特征分布的差异。负二项回归检验了发病率与诊断年份之间的关系。采用Cox比例风险回归模型，按诊断年份检查一年生存率。结果2020年，年龄标准化发病率（ASR，每10万名女性）为131.9，而2019年为163.9。与2019年相比，2020年的发病率明显下降（IRR = 0.41, 95 % CI = 0.22, 0.75）。与2019年相比，2020年通过有组织筛查出现的病例较少（-62.3 %），而通过其他方法出现症状的人数（0.1 %）和其他方法出现症状的人数（9.0 %）相似或增加。2019年和2020年之间，ER状态（p = 0.02）和分期（p <； 0.01）的病例分布存在显著差异。2014-2019年和2020年确诊病例的一年生存率相似（HR = 1.07, 95 % CI = 0.89, 1.27）。结论：这些发现表明，大流行爆发后浸润性乳腺癌发病率降低，一年生存率无差异。需要进一步研究以确定COVID-19的长期影响。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Examining the impact of the COVID-19 pandemic on invasive breast cancer incidence in Ireland: A population-based study

Background

This study aimed to investigate the COVID-19 impact on invasive breast cancer incidence and one-year survival in Ireland.

Methods

Anonymised aggregate population data from the National Cancer Registry Ireland were used to examine incidence between 2014 and 2020 and differences in the distribution of clinical characteristics using chi-squared tests. Negative binomial regression examined the association between incidence and year of diagnosis. One-year survival was examined by year of diagnosis using Cox proportional hazards regression modelling.

Results

For 2020, the age-standardised incidence rate (ASR, per 100,000 females) was 131.9, compared to 163.9 for 2019. In 2020, the incidence rate significantly declined (IRR = 0.41, 95 % CI = 0.22, 0.75) relative to 2019. Fewer cases presented through organised screening (-62.3 %), while similar or increased numbers presented with symptoms (0.1 %) and via other methods (9.0 %) respectively in 2020, compared to 2019. Significant differences were observed in case distribution by ER status (p = 0.02) and stage (p < 0.01) between 2019 and 2020. One-year survival was similar for cases diagnosed during 2014–2019 and in 2020 (HR = 1.07, 95 % CI = 0.89, 1.27).

Conclusions

These findings demonstrate reductions in invasive breast cancer incidence and no difference in one-year survival following the pandemic onset. Additional studies to determine the longer-term COVID-19 impact are needed.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Cancer Epidemiology 医学-肿瘤学

CiteScore

4.50

自引率

3.80%

发文量

200

审稿时长

39 days

期刊介绍： Cancer Epidemiology is dedicated to increasing understanding about cancer causes, prevention and control. The scope of the journal embraces all aspects of cancer epidemiology including: • Descriptive epidemiology • Studies of risk factors for disease initiation, development and prognosis • Screening and early detection • Prevention and control • Methodological issues The journal publishes original research articles (full length and short reports), systematic reviews and meta-analyses, editorials, commentaries and letters to the editor commenting on previously published research.